vs
Apellis Pharmaceuticals, Inc.（APLS）与FNB CORP（FNB）财务数据对比。点击上方公司名可切换其他公司
FNB CORP的季度营收约是Apellis Pharmaceuticals, Inc.的1.8倍（$366.0M vs $199.9M），FNB CORP净利率更高（45.9% vs -29.5%，领先75.4%），FNB CORP同比增速更快（13.7% vs -5.9%），FNB CORP自由现金流更多（$99.0M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 7.1%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
FNB集团是总部位于美国宾夕法尼亚州匹兹堡的多元化金融服务机构，为旗下最大子公司第一国民银行的控股主体，截至2025年12月31日总资产超500亿美元，业务覆盖匹兹堡、巴尔的摩、克利夫兰、华盛顿特区、北卡罗来纳州多座城市及南卡罗来纳州查尔斯顿等核心都会区。
APLS vs FNB — 直观对比
营收规模更大
FNB
是对方的1.8倍
$199.9M
营收增速更快
FNB
高出19.6%
-5.9%
净利率更高
FNB
高出75.4%
-29.5%
自由现金流更多
FNB
多$113.3M
$-14.3M
两年增速更快
APLS
近两年复合增速
7.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $366.0M |
| 净利润 | $-59.0M | $168.0M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | 45.1% |
| 净利率 | -29.5% | 45.9% |
| 营收同比 | -5.9% | 13.7% |
| 净利润同比 | -62.2% | 52.7% |
| 每股收益（稀释后） | $-0.40 | $0.47 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSFNB
| Q4 25 | $199.9M | $366.0M | ||
| Q3 25 | $458.6M | $359.0M | ||
| Q2 25 | $178.5M | $348.0M | ||
| Q1 25 | $166.8M | $323.0M | ||
| Q4 24 | $212.5M | $322.0M | ||
| Q3 24 | $196.8M | $323.0M | ||
| Q2 24 | $199.7M | $316.0M | ||
| Q1 24 | $172.3M | $319.0M |
净利润APLSFNB
| Q4 25 | $-59.0M | $168.0M | ||
| Q3 25 | $215.7M | $150.0M | ||
| Q2 25 | $-42.2M | $130.0M | ||
| Q1 25 | $-92.2M | $117.0M | ||
| Q4 24 | $-36.4M | $110.0M | ||
| Q3 24 | $-57.4M | $110.0M | ||
| Q2 24 | $-37.7M | $123.0M | ||
| Q1 24 | $-66.4M | $122.0M |
营业利润率APLSFNB
| Q4 25 | -25.6% | 45.1% | ||
| Q3 25 | 48.7% | 52.9% | ||
| Q2 25 | -18.6% | 47.7% | ||
| Q1 25 | -50.0% | 45.8% | ||
| Q4 24 | -12.3% | 31.7% | ||
| Q3 24 | -24.0% | 43.3% | ||
| Q2 24 | -14.7% | 49.7% | ||
| Q1 24 | -36.0% | 48.9% |
净利率APLSFNB
| Q4 25 | -29.5% | 45.9% | ||
| Q3 25 | 47.0% | 41.8% | ||
| Q2 25 | -23.6% | 37.4% | ||
| Q1 25 | -55.3% | 36.2% | ||
| Q4 24 | -17.1% | 34.2% | ||
| Q3 24 | -29.2% | 34.1% | ||
| Q2 24 | -18.9% | 38.9% | ||
| Q1 24 | -38.5% | 38.2% |
每股收益（稀释后）APLSFNB
| Q4 25 | $-0.40 | $0.47 | ||
| Q3 25 | $1.67 | $0.41 | ||
| Q2 25 | $-0.33 | $0.36 | ||
| Q1 25 | $-0.74 | $0.32 | ||
| Q4 24 | $-0.30 | $0.31 | ||
| Q3 24 | $-0.46 | $0.30 | ||
| Q2 24 | $-0.30 | $0.34 | ||
| Q1 24 | $-0.54 | $0.32 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $2.5B |
| 总债务越低越好 | — | $1.9B |
| 股东权益账面价值 | $370.1M | $6.8B |
| 总资产 | $1.1B | $50.2B |
| 负债/权益比越低杠杆越低 | — | 0.28× |
8季度趋势，按日历期对齐
现金及短期投资APLSFNB
| Q4 25 | $466.2M | $2.5B | ||
| Q3 25 | $479.2M | $2.4B | ||
| Q2 25 | $370.0M | $2.4B | ||
| Q1 25 | $358.4M | $2.4B | ||
| Q4 24 | $411.3M | $2.4B | ||
| Q3 24 | $396.9M | $2.1B | ||
| Q2 24 | $360.1M | $1.9B | ||
| Q1 24 | $325.9M | $1.5B |
总债务APLSFNB
| Q4 25 | — | $1.9B | ||
| Q3 25 | — | $2.1B | ||
| Q2 25 | — | $2.7B | ||
| Q1 25 | — | $2.5B | ||
| Q4 24 | — | $3.0B | ||
| Q3 24 | — | $2.5B | ||
| Q2 24 | — | $2.0B | ||
| Q1 24 | $93.1M | $2.1B |
股东权益APLSFNB
| Q4 25 | $370.1M | $6.8B | ||
| Q3 25 | $401.2M | $6.6B | ||
| Q2 25 | $156.3M | $6.5B | ||
| Q1 25 | $164.2M | $6.4B | ||
| Q4 24 | $228.5M | $6.3B | ||
| Q3 24 | $237.1M | $6.2B | ||
| Q2 24 | $264.3M | $6.1B | ||
| Q1 24 | $266.7M | $6.0B |
总资产APLSFNB
| Q4 25 | $1.1B | $50.2B | ||
| Q3 25 | $1.1B | $49.9B | ||
| Q2 25 | $821.4M | $49.7B | ||
| Q1 25 | $807.3M | $49.0B | ||
| Q4 24 | $885.1M | $48.6B | ||
| Q3 24 | $901.9M | $48.0B | ||
| Q2 24 | $904.5M | $47.7B | ||
| Q1 24 | $831.9M | $45.9B |
负债/权益比APLSFNB
| Q4 25 | — | 0.28× | ||
| Q3 25 | — | 0.32× | ||
| Q2 25 | — | 0.41× | ||
| Q1 25 | — | 0.39× | ||
| Q4 24 | — | 0.48× | ||
| Q3 24 | — | 0.40× | ||
| Q2 24 | — | 0.33× | ||
| Q1 24 | 0.35× | 0.35× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $128.0M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $99.0M |
| 自由现金流率自由现金流/营收 | -7.1% | 27.0% |
| 资本支出强度资本支出/营收 | 0.1% | 7.9% |
| 现金转化率经营现金流/净利润 | — | 0.76× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $376.0M |
8季度趋势，按日历期对齐
经营现金流APLSFNB
| Q4 25 | $-14.2M | $128.0M | ||
| Q3 25 | $108.5M | $167.0M | ||
| Q2 25 | $4.4M | $123.0M | ||
| Q1 25 | $-53.4M | $64.0M | ||
| Q4 24 | $19.4M | $326.0M | ||
| Q3 24 | $34.1M | $-14.0M | ||
| Q2 24 | $-8.3M | $85.0M | ||
| Q1 24 | $-133.0M | $245.0M |
自由现金流APLSFNB
| Q4 25 | $-14.3M | $99.0M | ||
| Q3 25 | $108.3M | $149.0M | ||
| Q2 25 | $4.4M | $85.0M | ||
| Q1 25 | $-53.4M | $43.0M | ||
| Q4 24 | $19.3M | $278.0M | ||
| Q3 24 | — | $-46.0M | ||
| Q2 24 | $-8.4M | $55.0M | ||
| Q1 24 | $-133.3M | $216.0M |
自由现金流率APLSFNB
| Q4 25 | -7.1% | 27.0% | ||
| Q3 25 | 23.6% | 41.5% | ||
| Q2 25 | 2.5% | 24.4% | ||
| Q1 25 | -32.0% | 13.3% | ||
| Q4 24 | 9.1% | 86.3% | ||
| Q3 24 | — | -14.2% | ||
| Q2 24 | -4.2% | 17.4% | ||
| Q1 24 | -77.3% | 67.7% |
资本支出强度APLSFNB
| Q4 25 | 0.1% | 7.9% | ||
| Q3 25 | 0.0% | 5.0% | ||
| Q2 25 | 0.0% | 10.9% | ||
| Q1 25 | 0.0% | 6.5% | ||
| Q4 24 | 0.0% | 14.9% | ||
| Q3 24 | 0.0% | 9.9% | ||
| Q2 24 | 0.0% | 9.5% | ||
| Q1 24 | 0.2% | 9.1% |
现金转化率APLSFNB
| Q4 25 | — | 0.76× | ||
| Q3 25 | 0.50× | 1.11× | ||
| Q2 25 | — | 0.95× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | — | 2.96× | ||
| Q3 24 | — | -0.13× | ||
| Q2 24 | — | 0.69× | ||
| Q1 24 | — | 2.01× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
FNB
暂无分部数据
